Abstract

Drugs prescribed for the treatment of moderate to severe inflammatory bowel disease (IBD) are associated with number of side effects. Targeted drug delivery is essential for the treatment of inflammatory bowel disease in order to increase efficacy and reduce toxicity. The established delivery system is designed on enzyme and time-based release of poorly soluble prednisolone, a drug of choice for the treatment of moderate to severe inflammatory bowel disease. Their pharmacological evaluation was done in 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced model of colitis in rat. The drug was administered once daily for 3 consecutive days. Visible severity of colitis, tissue to bodyweight ratio, tissue histology along with nitric oxide (NO), malondialdehyde (MDA) and myeloperoxidase (MPO) activity of colonic tissue were studied to estimate the efficacy of the drug-loaded delivery system. The highest efficacy was observed for formulation in which Eudragit RS100 (EU) was used along with guar gum (GG) in a ratio 2:5 for the preparation of delivery device. An effective recovery was observed from the study of tissue histology of animals treated with the drug-loaded optimized formulation and the biochemical parameters supported it. The toxicity of prednisolone (PD) was reduced significantly as predicted from thymus to body weight ratio of treated animals. GG and EU RS100 provided a newer bipolymer combination for the colon-targeted delivery of PD which increased its efficacy and reduced the toxic side effects. The in vivo experiments presented effective amelioration from colitis in TNBS-induced animal model of colitis.

Key words: Colon, eudragit RS100, guar gum, prednisolone, TNBS colitis

INTRODUCTION

Inflammatory bowel disease including ulcerative colitis and Crohn’s disease is becoming a severe, chronic, and refractory disease among the urban population in India.[1-4] The major causes may be attributed to various factors like genetic, environmental, and immune factors that affect the intestinal microflora and mucosal immune system.[5,6] Drugs of choice are mostly anti-inflammatory, antineoplastic drugs, and steroids that are readily absorbed from the upper part of the gastrointestinal tract (GIT) before reaching the desired site of action the colon and often get associated with multifarious side effects. There also several other drugs labile in the enzymatically active environment of the stomach and the small bowel. In order to formulate oral delivery system for these drugs, they need to be encapsulated within a delivery system that could protect the drug and allow its release in the colon. Site-specific delivery of an active pharmaceutical ingredient increases the bioavailability, reduces the amount of drug to be administered, and subsequently reduces the unwanted side effects. Prednisolone (PD) is the drug of choice prescribed in moderate to severe conditions of ulcerative colitis though it has number of side effects. PD is rapidly absorbed from stomach.[7] The biological t1/2 for PD is 2.5 h,[8,9] but pharmacokinetics of the drug reportedly follows a nonlinear pattern[10,11] and the biological absorption is influenced by multiple factors including food intake throughout the GIT.[12] In systemic circulation, PD remains predominantly protein bound leading to series of side effects.[13,14] Thus, site-specific delivery of PD is expected to reduce these unwanted side effects.

Extensive literature survey revealed the use of both natural and synthetic polymers for the preparation of delivery systems. These include pH, time- and enzyme-dependent polymers, or various combinations of these polymers in the form of coating and matrix forming materials.[15-22]
Our objective is to develop a colon-specific delivery system for PD using a combination of enzyme and time-dependent polymer for site-specific release of drug and effective amelioration of IBD. To formulate this drug delivery device we combined the properties of biodegradable polysaccharides with those of polyionic water insoluble pH-independent polymer with low porosity and inert to endogenous digestive secretions and enzymes. Here, guar gum has been used as an enzyme-dependent polymer and Eudragit RS100 as the time-dependent polymer that is expected to provide a colon specific release of PD. An optimized formulation has been developed on the basis of in vitro drug release profile of the prepared formulations and other physicochemical properties. This work is designed to study the in vivo efficacy and the usefulness of the site-specific drug delivery system for the treatment of inflammatory diseases of the colon.

**Materials and Methods**

**Materials**

GG (mannose to galactose ratio 1:2) was purchased from Merck India Ltd., EU was purchased from Evonik India Ltd., PD was obtained as a gift sample from Dey’s Medical Stores Mfg. Ltd., 2,4,6-trinitrobenzene sulphonic acid and reagents for biochemical analysis were purchased from Sigma Aldrich, USA. All other reagents and chemicals used were of Analytical Reagent grade (AR) and purchased locally.

Male Wister rats (6 weeks old, 200-210 g) were purchased from Central Ayurvedic Research Institute (Kolkata, India) and kept on normal diet with water ad libitum. The room temperature was maintained at 25 ± 1°C with relative humidity of 60% ± 5% and 12 h light-dark cycle. They were kept for 7 days without any treatment for acclimatization and from the 7th day onward they were used for the experiments. In vivo experiments were carried out in accordance with the guidelines of Committee for the Purpose of Control and Supervision on Experiments on Animals under Ministry of Forests (Animal Welfare Division) for conducting animal experiments. All efforts were made to minimize animal suffering and to limit the number of animal used. The experimental protocol was approved by the animal ethics committee, Department of Chemical Technology, University College of Science and Technology, University of Calcutta, with registration number 506/01/aCPCSEA and proposal number 02 dated 09/02/2010.

**Methods**

The matrix tablets were prepared as reported previously. Briefly, PD and different quantities of EU were dissolved together in 95% ethanol. Measured quantities of GG were mixed thoroughly with this solution. The mixture was dried for 30 min in a vacuum drier kept at 60 ± 1°C at 1 mm of mercury pressure. An aliquot of 5% aqueous GG solution was then added to it as binder and the mass was kept for 4 h at room temperature (22°C). The dough was then passed through a No. 20 sieve and dried for 15 min at 105 ± 5°C. The granules, thus, obtained were compressed into tablets with fillers in a Minipress II MT tablet punching machine (Kalveka, Rimek, India). As reported earlier, the matrix tablets were characterized through infrared spectroscopy (FT-IR), powder x-ray diffraction study (PXRD), atomic force microscopy (AFM), and in vitro drug release studies. An optimized formulation was achieved through statistical evaluation of release data using factorial design. The optimized formulation was further analyzed for its in vivo efficacy using rat model of colitis.

**In vivo efficacy study**

For in vivo efficacy study, a rat colitis model was developed using TNBS as the colitis inducing agent with slight modifications. The treatment schedule was presented in Figure 1. The rats were fasted for 48 h with free access to water. TNBS was instilled into the rat’s colon under light ether anesthesia. A baby feeding tube was inserted rectally into the colon in such a way that the tip was 8 cm proximal to the anus. Thereafter 0.6 mL of 5% w/v TNBS in 0.25 mL of 50% ethanol, resulting a total volume of 0.85 mL, was instilled into the lumen of the colon and the tube was flushed with 0.5 mL of air. This composition of TNBS solution gave a prompt inflammation in the prestudy experiment with uniform distribution throughout the colon and minimal mortality rate. Three days after TNBS treatment, the rats were weighed and those weighing 80-100% of their initial body weight (body weight before TNBS treatment) were used rejecting other rats from the in vivo studies. Another two groups of animals (Groups I and II) were maintained under similar environmental conditions without TNBS treatment. Group I served as healthy group. In Group II, 0.85 mL of 50% ethanol was administered to each animal into the colon using the technique as mentioned earlier and served as the solvent control group.

The above-mentioned rats with TNBS colitis were randomly allocated into five groups with six animals in each group. The groups were a) Control group (Group III) received only 1.0 mL of saline, b) void delivery device (GG-EU) group (Group IV) received void delivery system (EU and GG hydrogel without any drug (30 mg/day), as a suspension in 1 mL saline), c) PD group (Group V) received 5 mg PD/(kg/day), d) prednisolone loaded in guar gum matrix (GG-PD) group (Group VI) 5 mg PD equivalent/(kg/day) in delivery system containing only GG and f) prednisolone loaded in guar gum–eudragit RS100 bipolymer matrix (GG-EU-PD) group (Group VII) received 5 mg PD equivalent/(kg/day) in optimized delivery system. Each of the formulations and PD was suspended in 1.0 mL of saline. These were administered using gavages once daily from the fourth day after TNBS colitis induction and continued for 3 consecutive days. Three days after drug treatment, that is, on the

![Figure 1: Schedule for the development of colitis model and subsequent treatment with healing drug](image)
9th day, the rats were sacrificed using high dose of ether anesthesia. The large intestine, spleen, and thymus from each rat including the healthy and the solvent control group were excised and were immediately transferred into ice cold phosphate buffer saline and cleaned properly. The contents of large intestine were removed properly and cut open longitudinally in order to expose the mucosal surface. Extent of ulceration was noted. Each of these organs was weighed separately and kept refrigerated till further evaluation.

Severity of colitis was studied on the basis of visible damage to the colon, stool consistency, and rectal bleeding. The visual damage score was carried out as reported earlier [27,28] on a 0-5 scoring basis. Briefly, a score 0 was given for no visible damage, 1 for localized hyperaemia or ulcer, 2 for linear ulcers with no inflammation, 3 for inflammation on site, 4 for two or more sites of inflammation or ulceration, and 5 for 1 cm long heavy ulceration along the length of the colon. For stool consistency, a score 0 was given for well-formed pellets, 2 for pasty and semifomed stool, and 4 for liquid stool that stuck to anus. [29] The scoring for rectal bleeding was 0 for no visible blood in stool, 2 for finding blood, and 4 for gross bleeding. A mean colonic damage (MCD) was calculated as a mean of all three scores. [26]

The body weight was taken for each animal before sacrifice. After sacrifice the organs, colon, spleen, and thymus were collected and the weight of each organ was recorded and their ratios to the body weights were determined.

### Determination of biological markers in tissue homogenates

Another part of colonic tissue was washed thoroughly and homogenized in a ice-cold mixture of methanol and a 10% solution of trichloroacetic acid in the ratio of 1:1.5. The suspension was then centrifuged at 5000 rpm for 15 min in a cold centrifuge at 0°C. The supernatant was collected. Nitric oxide estimation was carried out using Griess reagent [1:1 mixture of sulfanilamide (1% w/v solution in 3M HCL) and 0.1% w/v solution of N-(1-naphthyl) ethylenediammine dihydrochloride as mentioned elsewhere. [30-32]

Malondialdehyde was determined as an indicator for lipid peroxidation. MDA was quantified by the measurement of thiobarbituric acid (TBA) reactive species. The concentration of tissue MDA was estimated using a standard curve prepared by using tetraethoxypropane (TEP) and TBA. [33,34]

Estimation of myeloperoxidase activity can give us an idea about the extent of tissue inflammation. MPO was estimated from the colonic tissue homogenates in ice-cold phosphate buffer following O-dianisidine method as mentioned elsewhere. [35,36] For calculation one unit of MPO activity was considered to be equivalent to 1 μmol of peroxide consumed per minute at 25°C.

### Plasma concentration of PD

Another set of rats were taken and as mentioned earlier after three days of TNBS treatment they were divided into two groups. They were fasted for 24 h. Then, PD alone was administered to the first group and GG-EU-PD to another group at a dose equivalent to 5 mg of PD per rat as a suspension in saline (1 mL per rat). Blood samples from the each rat were collected via jugular vein under light ether anesthesia immediately before and after 1, 2, 4, 8, 12, and 24 h. Plasma was collected after centrifuging the blood samples at 4000 rpm for 8 min in a cold centrifuge kept at 4°C. A total of 100 μL of saturated aqueous sodium chloride solution was mixed with 100 μL of plasma sample, 100 μL of 5% (w/v) phosphoric acid, and 4 mL mixture of tertiary butyl methyl ether and pentane (2:3, v/v) and the resulting mixture was shaken vigorously. Then, 3 mL of the organic phase was dried under nitrogen atmosphere at room temperature. [37] The resultant residue was dissolved in 1 mL of mobile phase and the amount of PD was analyzed by high performance liquid chromatography (HPLC).

### Statistical analysis

All values were presented as mean ± standard deviation. Student’s t-test and analysis of variance of the observed parameters were obtained to study the statistical significance of all data and a $P < 0.05$ was chosen as the level of significance.

### RESULTS

#### Evaluation of prednisolone tablets

The drug contents of each of the nine formulations (T1-T9) were estimated using a validated HPLC method [Table 1]. An in vitro cumulative drug release study was carried out in simulated colonic fluid containing rat cecal contents [Figure 2]. Formulations T3, T6, and T9 showed minimal initial burst release and the optimum drug release was observed for formulation T9 throughout the drug release study. The FT-IR studies presented no significant drug-polymer interaction [Figure 3]. The powder XRDS studies presented the entrapment of the drug in crystalline form within the polymer matrix [Figure 4]. The AFM studies presented the uniform distribution of PD within the polymer matrix when EU was used along with GG in the formulation of the matrix [Figure 5]. An optimized formulation was achieved through factorial design. [24] All in vivo experiments were carried out with the optimized formulation T9 [Table 1].

#### Table 1: Formulation, assay, and cumulative drug release of nine formulations

| Formulation | Amount of guar gum (mg) | Amount of Eudragit (mg) | Amount of drug (mg) | Assay % of total drug used in each formulation |
|-------------|-------------------------|-------------------------|---------------------|-----------------------------------------------|
| T1          | 570                     | 0                       | 166                 | 96.14                                         |
| T2          | 570                     | 160                     | 166                 | 96.12                                         |
| T3          | 570                     | 320                     | 166                 | 97.92                                         |
| T4          | 720                     | 0                       | 166                 | 96.74                                         |
| T5          | 720                     | 160                     | 166                 | 96.74                                         |
| T6          | 720                     | 320                     | 166                 | 98.32                                         |
| T7          | 870                     | 0                       | 166                 | 97.32                                         |
| T8          | 870                     | 160                     | 166                 | 96.99                                         |
| T9          | 870                     | 320                     | 166                 | 98.49                                         |
**In vivo efficacy study**

Intracolonic administration of TNBS in 50% ethanol resulted in an inflammatory response characterized by extensive disruption of the colonic mucosa, linear deep ulcers, haemorrhage, and submucosal edema [Figure 6b]. Diarrhea and rectal bleeding were evident in all rats receiving no treatment [Table 2].

The MCD data represented the mean visual severity of colitis. The extent of formation of ulcer and the extent of healing on drug treatment can be understood from MCD data. The diarrhea and the rectal bleeding were reduced significantly in all three drug-treated groups, the maximum being for GG-EU-PD group [Table 2]. It was also found that equivalent amount of PD loaded in the delivery device have got a higher efficacy in the healing process than that of the drug alone or loaded in GG.

---

**Table 2: Effect of drug on visual severity in rats with 2,4,6-trinitrobenzene sulphonic acid-induced colitis**

| Treatment group | Visual colonic damage score [0-5]* | Stool consistency [0-4]* | Rectal bleeding [0-4]* | Mean colonic damage [0-3.77]* |
|-----------------|-----------------------------------|--------------------------|------------------------|--------------------------------|
| Healthy         | 0                                  | 0                        | 0                      | 0                              |
| Solvent control | 0                                  | 0                        | 0                      | 0                              |
| Control         | 4.92±0.20                          | 4.00±0.00                | 1.10±0.90              | 3.36±2.90                      |
| GG-EU           | 4.50±0.45                          | 4.00±1.80                | 1.00±5.90              | 3.33±4.86                      |
| PD              | 3.31±0.40**                         | 2.00±0.30                | 0.70±0.40              | 2.42±3.60                      |
| GG-PD           | 3.75±0.42**                         | 0.90±0.40§               | 0.30±0.70§             | 1.80±1.73‡                     |
| GG-EU-PD        | 1.63±0.52†                          | 0.30±0.50§               | 0.00±0.10§             | 0.82±0.76§                     |

*Mean±standard deviation for six observations. **P < 0.01 as compared with the control group; †P < 0.05 as compared with the control group; ‡P < 0.01 as compared with prednisolone group. EU: Eudragit, GG: Guar gum, PD: Prednisolone.
matrix. The colon to body weight ratio also supported the above results [Table 3].

The value for GG-EU-PD group was close to the healthy group. The spleen to body weight ratio and thymus to body weight ratio also presented a similar ameliorative effect [Table 3].

There was no sign of ulcer formation in the colon of healthy animals. Formation of deep linear ulcer could be seen in the colon of the TNBS control group of animals. In case of PD group and GG-PD of animals, the extensive ulcer partially subsided. No sign of deep ulcer was observed in GG-EU-PD-treated group. Only mild inflammation of with signs of healing was observed visually [Figure 6].

**Microscopic analysis of the colon tissue samples and histological assessment**

Microscopic studies of haematoxylin and eosin-stained colon tissue sections of TNBS control group of animals showed extensive formation of ulcer with infiltration of inflammatory cells mostly neutrophils with moderate lymphoid tissue hyperplasia. However, no dysplasia of lining epithelium and fibrosis was observed. In GG-EU group ulcer formation with acute inflammatory cell infiltration was observed. In the PD group, acute inflammation partially subsided with partial healing of ulcer was observed. Partial healing was also observed in the colonic tissue section of GG-PD group. The GG-EU-PD-treated group showed moderate improvement [Figure 7]. The lymphoid tissue hyperplasia remained unaltered and mild development of dysplasia of the lining epithelium was observed in all the

---

**Figure 4:** XRD spectrum of prednisolone (a), GG (b), Eudragit (c), polymer combination (d), formulation T9 (e)

**Figure 5:** AFM images of formulation T1 (a), T9 (b), and Guar gum (c)
De, et al.: Site specific delivery of prednisolone increases efficacy and reduces toxicity

Figure 7: Representative histological appearance of rat colon: Normal colon of healthy rats at 10× magnification (a) and 40× magnification (b), Colon of 2,4,6-trinitrobenzene sulphonic acid-induced colitis group at 10× magnification (c), and 40× magnification (d), prednisolone treated colon of rats at 10× magnification (e), and at 40× magnification (f), prednisolone loaded in guar gum matrix-treated colon of rats at 10× magnification (g) and at 40× magnification (h), prednisolone loaded in guar gum-eudragit RS100 bipolymer matrix-treated colon of rats at 10× magnification (i), and at 40× magnification (j)

Table 3: Weight ratios of colon, spleen, and thymus to body weight

| Treatment group | (Colon/body weight)*100 | (Spleen/body weight)*100 | (Thymus/body weight)*100 |
|-----------------|--------------------------|--------------------------|--------------------------|
| Healthy         | 2.17±1.67                | 1.80±0.89                | 0.30±0.12                |
| Solvent control | 3.01±1.98                | 2.09±2.01                | 0.27±0.09                |
| Control group   | 6.96±4.89                | 2.57±1.67                | 0.09±0.05                |
| GG-EU           | 7.01±3.99                | 3.56±1.89                | 0.10±0.07                |
| PD              | 6.17±2.67                | 2.38±0.59                | 0.05±0.01                |
| GG-PD           | 5.99±2.78\*              | 2.12±0.67                | 0.12±0.19                |
| GG-EU-PD        | 3.94±2.22\*              | 2.10±0.11\*              | 0.29±0.09\*              |

The values are mean±standard deviation (n = 6 observations). *P < 0.05 as compared with the control group, \( P < 0.001 \) as compared with the control group, \( \dagger \) the difference with control group is insignificant. EU: Eudragit, GG: Guar gum, PD: Prednisolone

Biochemical parameters

Three drug-treated groups. The infiltration of inflammatory cells and severity of colitis was reduced significantly in case of the GG-EU-PD-treated group [Figure 7]. No fibrosis was observed in each group of animals. However, no ulcer formation was observed in the colonic tissue of healthy group and solvent control group, only mild reactive lymphoid tissue hyperplasia was observed.

MPO has been a plentiful constituent for neutrophils, its estimation can give us an idea of tissue neutrophil content.\(^{[35]}\) The accumulation of neutrophil was a characteristic of inflamed tissue.\(^{[36]}\) In the sites of inflammation, accumulation of neutrophil occurs to engulf or ingest the infective cells. The control group was also characterized by an increase of MPO activity which was reduced significantly for the GG-EU-PD group revealing lesser accumulation of MPO and initiation of healing. The value for MDA was also reduced significantly on drug treatment, the maximum reduction being for GG-EU-PD group 1.31 n mole/g [Table 3].

Plasma concentration of prednisolone

In order to study whether any portion of PD loaded in GG-EU-PD formulation enters into blood circulation, the dosage form was administered into TNBS instilled rats. PD alone at a dose of 5 mg PD equivalent/kg was administered to second group of animals to compare the effect of loading PD into the delivery system. The blood samples were collected and the plasma concentration of PD verses time graph was plotted as presented in Figure 4. It was observed that for free PD, the drug release took place almost instantly and it reached a value of 1.92 μg/mL.
within 2 h that declined sharply and reduced to almost zero at the 8th h of study. After which, no further blood level of PD was observed up to 24 h. In case of GG-EU-PD, the plasma level of PD was very low of about 0.53 μg/mL after 2 h of study and it declined sharply to 0 μg/mL within 4 h of study [Figure 8].

**DISCUSSION**

The current study was conducted in order to develop a localized drug delivery system for PD. Anti-inflammatory steroids like PD was associated with a number of side effects and designing localized delivery system would reduce gastrointestinal absorption from undesired location of GIT.[17] In our study, the formulation batches were analyzed using a validated HPLC procedure and the drug load was found to be between 96.14% and 98.49% [Table 1]. The optimized formulation T9 achieved through factorial design[24] was used for in vivo efficacy study. The treatment of PD loaded in optimized drug delivery device on rat model of colitis revealed a possible localized delivery of the healing drug at the desired site of action. This markedly reduced the signs of inflammation and ulceration as revealed by macroscopic, histological, and biochemical parameters studied. The results were compared with PD alone or with PD loaded in GG. The macroscopic damage score was found to be much lower for GG-EU-PD group compared with GG-PD group or PD group suggesting that greater amount of drug has been delivered to colon, resulting in better healing at the diseased site with GG-EU-PD group.[17] The colon to body weight ratio and thymus to body weight ratio for GG-EU-PD group was close to healthy group indicating the reduced toxic side effects of PD[36] which was observed with PD group. This was lower than the control group. Thymus to body weight ratio was higher for GG-EU-PD group than all other groups studied and was close to healthy group indicating the reduced toxic side effects of PD[36]. Thymus to body weight ratio was higher for GG-EU-PD group compared with healthy group indicating the efficacy of PD loaded in GG and EU RS100 bipolymeric delivery device. Reduction in thymus to body weight ratio below those for normal animals was considered to be due to unwanted side effects of PD[36] which was observed with PD group. NO estimated from inflamed colonic tissue of TNBS control group of animals was much higher than normal. The same for GG-EU-PD group was close to normal group of animals. This indicates the reactive moieties of the active metabolites of nitrogen decreased sharply on GG-EU-PD[31] treatment. NO was also higher in the PD and GG-PD group since much of the drug may have been absorbed from the gut prior to reaching the colon with PD and GG-PD compared with the efficacious GG-EU-PD treatment.

The histological study also supported the data with a clear sign of better healing of ulcer with GG-EU-PD group. The mild dysplasia of the lining epithelium may be due to rapid proliferation of the cells due to rapid healing of the damaged mucosa.

The plasma concentration of PD in the GG-EU-PD-treated group was also negligible indicating the possible localized release with GG-PD group or PD group suggesting that greater amount of drug has been delivered to colon, resulting in better healing at the diseased site with GG-EU-PD group.[17] The colon to body weight ratio and thymus to body weight ratio for GG-EU-PD group was close to healthy group indicating the efficacy of PD loaded in GG and EU RS100 bipolymeric delivery device. Reduction in thymus to body weight ratio below those for normal animals was considered to be due to unwanted side effects of PD[36] which was observed with PD group. This was lower than the control group. Thymus to body weight ratio was higher for GG-EU-PD group than all other groups studied and was close to healthy group indicating the reduced toxic side effects of PD[36]. Thymus to body weight ratio was higher for GG-EU-PD group compared with the efficacious GG-EU-PD treatment.

**Table 4: Biochemical analysis of colonic tissue homogenates**

| Treatment group | NO (n mole/g of wet tissue)* | MDA (n mole/g of wet tissue)* | MPO Units/g of wet tissue |
|-----------------|-----------------------------|-----------------------------|--------------------------|
| Healthy         | 0.39±2.89                   | 0.43±2.41                   | 0.15±0.32                |
| Solvent control | 0.48±2.01                   | 0.55±1.77                   | 0.19±0.89                |
| Control group   | 3.49±2.38                   | 7.60±1.2                    | 0.46±0.38                |
| GG-EU           | 3.93±2.98                   | 7.89±0.89                   | 0.44±0.24                |
| PD              | 3.01±1.92                   | 4.56±2.01                   | 0.22±0.04                |
| GG-PD           | 2.89±1.54                   | 2.49±2.89                   | 0.23±0.19                |
| GG-EU-PD        | 1.91±2.57                   | 1.31±1.73                   | 0.16±0.04                |

*The values are mean±standard deviation (n=6 observations). †P < 0.05 in comparison with the control group, ††P < 0.05 in comparison with free prednisolone treatment, **P < 0.05 compared to prednisolone loaded in guar gum matrix group. EU: Eudragit, GG: Guar gum, PD: Prednisolone, MDA: Malondialdehyde, MPO: myeloperoxidase, NO: Nitric oxide

Figure 8: Plasma concentration-time graph of prednisolone after oral administration of prednisolone in delivery system and prednisolone alone. The data are represented as the mean ± standard deviation (n=3)
of the drug into the colonic mucosa before coming into blood stream. In case of PD group, the drug may have been released at the upper part of the GIT resulting in a sharp increase in the plasma concentration which also decreased sharply after getting protein bound,\textsuperscript{7,8} thereby making it unavailable at the desired site of action.

**CONCLUSION**

The treatment with PD-loaded-optimized bipolymer combination markedly ameliorates the inflammation in rat model of colitis. The delivery system allowed the localized delivery and prevented the early release of PD. The tissue macroscopic and microscopic studies and the observed biochemical parameters predict the efficacy and potential of the colonic delivery system for PD along with a reduction of toxic side effects. This bipolymer combination can be further studied and used for the development of newer colon-targeted delivery systems for other drugs having therapeutic efficacy and toxic side effects.

**ACKNOWLEDGMENT**

The authors acknowledge the contribution of Scientific and Clinical Research Laboratory, Kolkata and Dr. Subir Kumar Dutta in the assessment of the colon tissue sections. The authors also acknowledge the kind support of Dr. Achinta Saha for his valuable advice in the biochemical analysis wherever required.

**REFERENCES**

1. Ray G. Inflammatory bowel disease in India—changing paradigms. Int J Colorectal Dis 2011;26:635-44.
2. Probert CS, Mayberry JF, Mann R. Inflammatory bowel disease in the rural Indian subcontinent: A survey of patients attending mission hospitals. Digestion 1990;47:42-6.
3. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587-90.
4. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008;103:3167-82.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
6. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: Lessons for complex diseases? Lancet 2006;367:1271-84.
7. Carpani de Kaski M, Rentsch R, Levi S, Hodgson HJ. Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut 1995;37:613-6.
8. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001;41:1180-94.
9. Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharm Biopharm 1981;9:389-416.
10. Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephritic syndrome during active phase and in remission. Br J Clin Pharmac 1984;17:423-31.
11. Al-Habet SM, Taraporewala IB, Lee HJ. Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. Drug Metab Dispos 1990;18:55-60.
12. Al-Habet SM, Rogers HJ. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur J Clin Pharmacol 1990;37:423-6.
13. Reece PA, Disney AP, Stafford I, Shastry JC. Prednisolone protein binding in renal transplant patients. Br J Clin Pharmac 1985;20:159-62.
14. Severn PS, Fraser SG. Bilateral cataracts and glaucoma induced by long-term use of oral prednisolone bought over the internet. Lancet 2006;368:818.
15. Ibeke VC, Fadda HM, Parsons GE, Basit AW. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm 2006;308:52-60.
16. Friend DR. New oral delivery systems for inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:247-65.
17. Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: An in-vitro release model. J Pharm Pharmacol 2005;57:709-19.
18. Zhang SQ, Rahman Z, Thumma S, Repka MA, Chen GH, Li SM. Development and evaluation of a pH-dependent sustained release tablet for irritable bowel syndrome. Drug Dev Ind Pharm 2009;35:57-64.
19. Mundargi RC, Patil SA, Agnihotri S, Aminabhavi TM. Development of polysaccharide–based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm 2007;33:255-64.
20. Ji C, Xu H, Wu W. In vitro evaluation and pharmacokinetics in dogs of guar gum and eudragit FS30D –coated colon targeted pellets of indomethacin. J Drug Target 2007;15:123-31.
21. Moustafine RI, Salachova AR, Frolova ES, Kemenova VA, Mooter GV. Interpolyelectrolyte complex of eudragit EPO with sodium alginate as potential carriers for colonic drug delivery: Evaluation and pharmacokinetics in dogs of guar gum and eudragit FS30D –coated colon targeted pellets of indomethacin. J Drug Target 2007;15:123-31.
22. Li K, Kim K, Kim J, Hwang J, Joo Y. Studies of in situ gelling and erosion of mucoadhesive microspheres. Eur J Pharm Biopharm 1999;47:181-8.
23. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten — induced model of colonic inflammation and ulceration in the rat colon. Gastroenterology 1990;96:795-803.
24. Al-Habet SM, Rogers HJ. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur J Clin Pharmacol 1990;37:423-6.
25. Reece PA, Disney AP, Stafford I, Shastry JC. Prednisolone protein binding in renal transplant patients. Br J Clin Pharmac 1985;20:159-62.
26. Severn PS, Fraser SG. Bilateral cataracts and glaucoma induced by long-term use of oral prednisolone bought over the internet. Lancet 2006;368:818.
27. Ibeke VC, Fadda HM, Parsons GE, Basit AW. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm 2006;308:52-60.
28. Friend DR. New oral delivery systems for inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:247-65.
29. Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: An in-vitro release model. J Pharm Pharmacol 2005;57:709-19.
30. Zhang SQ, Rahman Z, Thumma S, Repka MA, Chen GH, Li SM. Development and evaluation of a pH-dependent sustained release tablet for irritable bowel syndrome. Drug Dev Ind Pharm 2009;35:57-64.
31. Mundargi RC, Patil SA, Agnihotri S, Aminabhavi TM. Development of polysaccharide–based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm 2007;33:255-64.
32. Ji C, Xu H, Wu W. In vitro evaluation and pharmacokinetics in dogs of guar gum and eudragit FS30D –coated colon targeted pellets of indomethacin. J Drug Target 2007;15:123-31.
33. Moustafine RI, Salachova AR, Frolova ES, Kemenova VA, Mooter GV. Interpolyelectrolyte complex of eudragit EPO with sodium alginate as potential carriers for colonic drug delivery: Evaluation and pharmacokinetics in dogs of guar gum and eudragit FS30D –coated colon targeted pellets of indomethacin. J Drug Target 2007;15:123-31.
34. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten — induced model of colonic inflammation and ulceration in the rat colon. Gastroenterology 1990;96:795-803.
28. Tozoki H, Fujita T, Odoriba T, Terabe A, Okabe S, Muranishi S, et al. Validation of pharmacokinetic model of colon specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-Trinitrobenzenesulphonic acid induced colitis in rats. J Pharm Pharmacol 1999;51:1107-12.

29. Lampretch A, Ulbrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmaco Exp Ther 2001;299:755-81.

30. Kleinbongard P, Rassaf T, Dejam A, Kerber S, Kelm M. Griess method for nitrite measurement of aqueous and protein-containing samples. Methods Enzymol 2002;359:158-68.

31. Ferretti M, Gionchetti P, Rizzello F, Venturi A, Stella P, Corti F, et al. Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Dig Dis Sci 1997;42:2606-11.

32. Mei Q, Xu JM, Xiang L, Hu YM, Hu XP, Hu ZW. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J 2010;81:667-72.

33. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thioarbituric acid reaction. Anal Biochem 1979;95:351-58.

34. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990;9:515-40.

35. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-9.

36. Pertuit D, Moula B, Betz T, Nadaradjane A, Neumann D, Ismaili L, et al. 5-amino salicylic acid bound nanoparticles for therapy of inflammatory bowel disease. J Control Release 2007;123:211-8.

37. Oosegi T, Onishi H, Machida Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int J Pharm 2008;348:80-8.